DelveInsight’s, “Motor Neuron Disease Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the Motor Neuron Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Motor Neuron Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Motor Neuron Disease Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Motor Neuron Disease Pipeline Outlook Report

Key Takeaways from the Motor Neuron Disease Pipeline Report

• In July 2025, AL-S Pharma conducted a study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
• In July 2025, Biojiva LLC conducted a Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis.
• DelveInsight’s Motor Neuron Disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Motor Neuron Disease treatment.
• The leading Motor Neuron Disease Companies such as Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd., Transposon Therapeutics, Inc., GeneCradle Therapeutics, Verge Genomics, QurAlis Corporation, Zydus Lifesciences Limited, Ra Pharmaceuticals, Guangzhou Magpie Pharmaceuticals Co., Ltd., Scholar Rock, Inc., Spinogenix, Seelos Therapeutics, Inc., Sanofi, Hoffmann-La Roche, Revalesio Corporation, Cytokinetics, Rapa Therapeutics LLC, Q Therapeutics, Inc., PTC Therapeutics, ProJenX, NeuroSense Therapeutics Ltd., Knopp Biosciences, MediciNova, Amylyx Pharmaceuticals Inc., Neuropore Therapies Inc, NMD Pharma A/S, Supernus Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma America Inc., MaaT Pharma and others.
• Promising Motor Neuron Disease Pipeline Therapies such as Trimetazidine Dihydrochloride, MD1003, Levetiracetam, Tocilizumab, AMX0035, 3K3A-APC Protein, GM604 and others.

Discover how the Motor Neuron Disease treatment paradigm is evolving. Access DelveInsight’s in-depth Motor Neuron Disease Pipeline Analysis for a closer look at promising breakthroughs @ Motor Neuron Disease Clinical Trials and Studies

Motor Neuron Disease Emerging Drugs Profile

• Talditercept alfa: Biohaven Pharmaceuticals, Inc.

Taldefgrobep alfa (also known as BMS-986089) is a modified adnectin designed to specifically bind to myostatin (GDF-8). Adnectins are an established proprietary protein therapeutic class based on human fibronectin, an extracellular protein that is naturally abundant in human serum. The intrinsic properties of an adnectin align with the properties needed to make a successful drug, including high potency, specificity, stability, and favorable half-life. Currently, the drug is in Phase III stage of its development for the treatment of Spinal Muscular Atrophy.

• Pridopidine: Prilenia Therapeutics

Pridopidine is an oral investigational drug. It is administered in a small, easy-to-swallow capsule twice daily. Multiple clinical studies have been conducted providing important understanding about pridopidine’s safety, mechanism of action, and efficacy. Imaging studies in humans show that pridopidine enters the brain and spinal cord, where it activates a protein called the sigma-1 receptor (S1R). Currently, the drug is in Phase II/III stage of its development for the treatment of Amyotrophic lateral sclerosis.

• VM202: Helixmith Co., Ltd.

Engensis (VM202) is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. It is non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. Data from previous clinical studies suggest that Engensis is well tolerated and has the potential to provide durable analgesic and/or symptomatic relief in a variety of disease settings. Currently, the drug is in Phase II stage of its development for the treatment of Amyotrophic lateral sclerosis.

• TPN-101: Transposon Therapeutics, Inc.

TPN-101, is the most potent known small molecule that is inhibitor of LINE-1 reverse transcriptase and has excellent systemic and brain bioavailability with once daily oral dosing. TPN-101, also known as censavudine. Currently, the drug is in Phase II stage of its development for the treatment of Amyotrophic lateral sclerosis.

• GC 101: GeneCradle Therapeutics

GC101 injection is a gene replacement therapy drug based on AAV viral vector. Its structure and administration method are optimized according to the disease characteristics and biodistribution characteristics to achieve safer and more effective purposes. The drug candidate is been developed by GeneCradle Therapeutics. Currently, the drug is in Phase I/II stage of its development for the treatment of Spinal muscular atrophy.

• VRG 50635: Verge Genomics

VRG50635 is a potent, orally bioavailable PIKfyve inhibitor that improves survival in ALS patient neurons and has shown efficacy in multiple preclinical studies in ALS-relevant models of motor neuron degeneration. VRG50635 is the only PIKfyve inhibitor in clinical development that has been specifically optimized for treatment of central nervous system disorders like ALS, and has the potential to become a best-in-class therapy. Currently, the drug is in Phase I stage of its development for the treatment of Spinal muscular atrophy.

• QRL 201: QurAlis Corporation

QRL-201 is a first-in-class precision therapeutic product candidate aiming to restore STATHMIN-2 (STMN2) expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability and is the most significantly regulated gene by TDP-43 exclusively in humans. Its expression is significantly decreased in nearly all ALS patients and it is the most consistently decreased gene over all sporadic ALS patient data sets. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. Currently, the drug is in Phase I stage of its development for the treatment of Amyotrophic lateral sclerosis.

The Motor Neuron Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Motor Neuron Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Motor Neuron Disease Treatment.
• Motor Neuron Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Motor Neuron Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Motor Neuron Disease market.

Get a detailed analysis of the latest innovations in the Motor Neuron Disease pipeline. Explore DelveInsight’s expert-driven report today! @ Motor Neuron Disease Unmet Needs

Motor Neuron Disease Companies

Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd., Transposon Therapeutics, Inc., GeneCradle Therapeutics, Verge Genomics, QurAlis Corporation, Zydus Lifesciences Limited, Ra Pharmaceuticals, Guangzhou Magpie Pharmaceuticals Co., Ltd., Scholar Rock, Inc., Spinogenix, Seelos Therapeutics, Inc., Sanofi, Hoffmann-La Roche, Revalesio Corporation, Cytokinetics, Rapa Therapeutics LLC, Q Therapeutics, Inc., PTC Therapeutics, ProJenX, NeuroSense Therapeutics Ltd., Knopp Biosciences, MediciNova, Amylyx Pharmaceuticals Inc., Neuropore Therapies Inc, NMD Pharma A/S, Supernus Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma America Inc., MaaT Pharma and others.

Motor Neuron Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Motor Neuron Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Motor Neuron Disease Therapies and key Developments @ Motor Neuron Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Motor Neuron Disease Pipeline Report

• Coverage- Global
• Motor Neuron Disease Companies- Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd., Transposon Therapeutics, Inc., GeneCradle Therapeutics, Verge Genomics, QurAlis Corporation, Zydus Lifesciences Limited, Ra Pharmaceuticals, Guangzhou Magpie Pharmaceuticals Co., Ltd., Scholar Rock, Inc., Spinogenix, Seelos Therapeutics, Inc., Sanofi, Hoffmann-La Roche, Revalesio Corporation, Cytokinetics, Rapa Therapeutics LLC, Q Therapeutics, Inc., PTC Therapeutics, ProJenX, NeuroSense Therapeutics Ltd., Knopp Biosciences, MediciNova, Amylyx Pharmaceuticals Inc., Neuropore Therapies Inc, NMD Pharma A/S, Supernus Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma America Inc., MaaT Pharma and others.
• Motor Neuron Disease Pipeline Therapies- Trimetazidine Dihydrochloride, MD1003, Levetiracetam, Tocilizumab, AMX0035, 3K3A-APC Protein, GM604 and others.
• Motor Neuron Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Motor Neuron Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Motor Neuron Disease drug development? Find out in DelveInsight’s exclusive Motor Neuron Disease Pipeline Report—access it now! @ Motor Neuron Disease Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Motor Neuron Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Motor Neuron Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Talditercept alfa: Biohaven Pharmaceuticals, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. VM202: Helixmith Co., Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. GC 101: GeneCradle Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Motor Neuron Disease Key Companies
21. Motor Neuron Disease Key Products
22. Motor Neuron Disease- Unmet Needs
23. Motor Neuron Disease- Market Drivers and Barriers
24. Motor Neuron Disease- Future Perspectives and Conclusion
25. Motor Neuron Disease Analyst Views
26. Motor Neuron Disease Key Companies
27. 27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth Curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/motor-neuron-disease-pipeline-insight